Skip to main content
Journal cover image

Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes.

Publication ,  Journal Article
Usman, A; Bliden, KP; Cho, A; Walia, N; Jerjian, C; Singh, A; Kundan, P; Duhan, S; Tantry, US; Gurbel, PA
Published in: J Thromb Thrombolysis
February 2022

Diabetes mellitus (DM) is associated with a greater risk of COVID-19 and an increased mortality when the disease is contracted. Metformin use in patients with DM is associated with less COVID-19-related mortality, but the underlying mechanism behind this association remains unclear. Our aim was to explore the effects of metformin on markers of inflammation, oxidative stress, and hypercoagulability, and on clinical outcomes. Patients with DM on metformin (n = 34) and metformin naïve (n = 41), and patients without DM (n = 73) were enrolled within 48 h of hospital admission for COVID-19. Patients on metformin compared to naïve patients had a lower white blood cell count (p = 0.02), d-dimer (p = 0.04), urinary 11-dehydro thromboxane B2 (p = 0.01) and urinary liver-type fatty acid binding protein (p = 0.03) levels and had lower sequential organ failure assessment score (p = 0.002), and intubation rate (p = 0.03), fewer hospitalized days (p = 0.13), lower in-hospital mortality (p = 0.12) and lower mortality plus nonfatal thrombotic event occurrences (p = 0.10). Patients on metformin had similar clinical outcomes compared to patients without DM. In a multiple regression analysis, metformin use was associated with less days in hospital and lower intubation rate. In conclusion, metformin treatment in COVID-19 patients with DM was associated with lower markers of inflammation, renal ischemia, and thrombosis, and fewer hospitalized days and intubation requirement. Further focused studies are required to support these findings.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Thromb Thrombolysis

DOI

EISSN

1573-742X

Publication Date

February 2022

Volume

53

Issue

2

Start / End Page

363 / 371

Location

Netherlands

Related Subject Headings

  • Thrombosis
  • Retrospective Studies
  • Oxidative Stress
  • Metformin
  • Inflammation
  • Hypoglycemic Agents
  • Humans
  • Hospitalization
  • Diabetes Mellitus
  • Cardiovascular System & Hematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Usman, A., Bliden, K. P., Cho, A., Walia, N., Jerjian, C., Singh, A., … Gurbel, P. A. (2022). Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes. J Thromb Thrombolysis, 53(2), 363–371. https://doi.org/10.1007/s11239-022-02631-7
Usman, Abira, Kevin P. Bliden, Alastair Cho, Naval Walia, Christophe Jerjian, Arvind Singh, Parshotam Kundan, Sanchit Duhan, Udaya S. Tantry, and Paul A. Gurbel. “Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes.J Thromb Thrombolysis 53, no. 2 (February 2022): 363–71. https://doi.org/10.1007/s11239-022-02631-7.
Usman A, Bliden KP, Cho A, Walia N, Jerjian C, Singh A, et al. Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes. J Thromb Thrombolysis. 2022 Feb;53(2):363–71.
Usman, Abira, et al. “Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes.J Thromb Thrombolysis, vol. 53, no. 2, Feb. 2022, pp. 363–71. Pubmed, doi:10.1007/s11239-022-02631-7.
Usman A, Bliden KP, Cho A, Walia N, Jerjian C, Singh A, Kundan P, Duhan S, Tantry US, Gurbel PA. Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes. J Thromb Thrombolysis. 2022 Feb;53(2):363–371.
Journal cover image

Published In

J Thromb Thrombolysis

DOI

EISSN

1573-742X

Publication Date

February 2022

Volume

53

Issue

2

Start / End Page

363 / 371

Location

Netherlands

Related Subject Headings

  • Thrombosis
  • Retrospective Studies
  • Oxidative Stress
  • Metformin
  • Inflammation
  • Hypoglycemic Agents
  • Humans
  • Hospitalization
  • Diabetes Mellitus
  • Cardiovascular System & Hematology